CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 11,112 Shares

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 11,112 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $12.28, for a total value of $136,455.36. Following the completion of the transaction, the chief technology officer directly owned 167,704 shares of the company’s stock, valued at approximately $2,059,405.12. The trade was a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Raymond Woo also recently made the following trade(s):

• On Friday, October 3rd, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $12.54, for a total value of $139,344.48.

CeriBell Stock Down 2.9%

CeriBell stock traded down $0.38 during trading hours on Thursday, reaching $12.48. The stock had a trading volume of 183,260 shares, compared to its average volume of 288,063. The company has a market cap of $462.82 million and a price-to-earnings ratio of -8.25. The business’s 50 day moving average price is $12.11 and its 200-day moving average price is $14.50. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. The firm had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. CeriBell has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. KLP Kapitalforvaltning AS acquired a new stake in CeriBell during the first quarter worth about $36,000. Tower Research Capital LLC TRC lifted its holdings in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the period. Ameritas Investment Partners Inc. boosted its position in CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of CeriBell during the 1st quarter worth approximately $67,000. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of CeriBell by 161.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after purchasing an additional 3,502 shares in the last quarter.

Wall Street Analyst Weigh In

CBLL has been the subject of several analyst reports. JPMorgan Chase & Co. decreased their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Raymond James Financial assumed coverage on CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price on the stock. TD Cowen lowered their price target on CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $25.17.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.